Urea or thiourea compound and preparation and application thereof

By designing and synthesizing urea or thiourea compounds, the problems of poor efficacy and major side effects of existing βGUS inhibitors are solved, and efficient and safe treatment of gastrointestinal adverse reactions are achieved, which simplifies the preparation process and expands the application prospects.

CN118908911AActive Publication Date: 2024-11-08ZHEJIANG UNIV OF TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410949580.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

The existing β-glucuronidase (βGUS) inhibitors have poor efficacy and great side effects during drug use, making it difficult to effectively alleviate gastrointestinal adverse events.

Method used

A series of novel structures of urea or thiourea compounds were designed and synthesized, and carried out in specific solvents through room temperature reaction or heating reaction. A simple preparation method was used to significantly inhibit βGUS activity, which was used as a βGUS inhibitor for the treatment of gastrointestinal deficits. reaction.

Benefits of technology

Provides efficient and safe βGUS inhibitors, significantly improves the therapeutic effect of gastrointestinal adverse reactions, simplifies the preparation process, improves yields, and expands the benzozole heterocyclic and substituted benzene structure in βGUS inhibitors Application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908911A_ABST
    Figure CN118908911A_ABST
Patent Text Reader

Abstract

The invention discloses a urea or thiourea compound as well as a preparation method and application thereof, the structural general formula of the compound is shown as a formula (I), a formula (II) and a formula (III), and the compound has excellent beta-glucuronidase (beta GUS) inhibitory activity, can be used as a beta GUS activity inhibitor, and can be clinically used as a therapeutic drug for serious adverse reaction of gastrointestinal tracts. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

(I) Technical field

[0001] The invention belongs to the field of pharmaceutical chemistry, and particularly relates to urea or thiourea compounds and preparation methods and applications thereof. (II) Background technology

[0002] Gastrointestinal adverse events (GIAEs) have always been one of the serious problems in human survival and development. Studies have found that excessive activity of β-glucuronidase (βGUS) is the main cause of the above problems. Inhibiting its excessive activity can effectively alleviate serious adverse events (SAEs) such as diarrhea, vomiting and loss of appetite that occur during the use of drugs. It can be seen that the use of βGUS inhibitors can effectively solve the above problems. However, the currently known βGUS inhibitors face problems such as poor efficacy and large side effects. Therefore, finding efficient and safe βGUS inhibitors should be the focus of current scientific research. (III) Summary of the invention

[0003] The present invention aims to provide a urea or thiourea compound and a preparation method and application thereof. A series of urea or thiourea compounds with novel structures are designed and synthesized using urea or thiourea as a leading skeleton. The urea or thiourea compounds have significant βGUS inhibitory activity and potential as βGUS inhibitors, and can be used for the development and utilization of drugs for treating severe gastrointestinal adverse reactions caused by β-glucuronidase.

[0004] The technical solution adopted by the present invention is:

[0005] The present invention provides a urea or thiourea compound, wherein the urea compound has a structure as shown in formula (I), and the thiourea compound has a structure as shown in formula (II) or (III):

[0006]

[0007] The R1 group in formula (Ⅰ) is one or more substituted, and the R1 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano; the R2 group in formula (Ⅱ) and the R3 group in formula (Ⅲ) are the same as the R1 group in formula (Ⅰ).

[0008] Further, the R1 group is 2-fluoro, 3-fluoro, 4-fluoro, 2-chloro, 3-chloro, 4-chloro, 2-bromo, 3-bromo, 4-bromo, 2-methyl, 3-methyl, 4-methyl, 3,5-dimethyl, 2-methoxy, 3-methoxy, 4-methoxy, 2-ethoxy, 3-ethoxy, 4-ethoxy, 2-trifluoromethyl, 3-trifluoromethyl, 4-trifluoromethyl, 2-trifluoromethoxy, 3-trifluoromethoxy or 4-trifluoromethoxy.

[0009] Furthermore, the R1 group is 2-fluoro, 3-fluoro, 4-fluoro, 2-chloro, 3-chloro, 4-chloro, 2-trifluoromethyl, 3-trifluoromethyl, 4-trifluoromethyl, 3,5-bis(trifluoromethyl) or 4-methoxy.

[0010] Further, the R2 group is 2-fluoro, 3-fluoro, 4-fluoro, 2-chloro, 3-chloro, 4-chloro, 2-trifluoromethyl, 3-trifluoromethyl, 4-trifluoromethyl, 3,5-bis(trifluoromethyl), 2-methoxy, 3-methoxy or 4-methoxy.

[0011] Furthermore, the R3 group is 2-fluoro, 3-fluoro, 4-fluoro, 2-chloro, 3-chloro, 4-chloro, 2-trifluoromethyl, 3-trifluoromethyl, 4-trifluoromethyl, 3,5-bis(trifluoromethyl), 2-methoxy, 3-methoxy or 4-methoxy.

[0012] The present invention also provides a method for preparing the urea compound represented by formula (I), the method comprising the following steps:

[0013]

[0014] In the presence of a solvent, after the compound of formula (A) and the compound of formula (B) are completely reacted at room temperature under magnetic stirring (preferably for 2 hours), there is no need to perform column chromatography separation and purification, and the solvent can be evaporated to obtain the compound of formula (I); the solvent is dichloromethane (CH2Cl2); the R1 group in the compound of formula (B) is one or more substituted, and the R1 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

[0015] That is, the following reaction occurs:

[0016]

[0017] Furthermore, the preparation method of the urea compound represented by formula (I) is carried out according to the following steps: adding the compound of formula (A) to a solvent, stirring and dissolving, slowly dropping the compound of formula (B), controlling the dropping speed to 2-4 mL / min, placing on a magnetic stirrer at room temperature to react for 2 hours, and performing thin layer chromatography monitoring with petroleum ether: ethyl acetate (PE: EA) with a volume ratio of 3:1 as a developing solvent during the reaction. The product exhibits a single absorption point under ultraviolet light, and the relative shift value (R fThe reaction is complete when the reaction mixture is molten by a rotary evaporator without the need for column chromatography separation and purification. The solvent can be evaporated to dryness by naturally evaporating the flask overnight in a fume hood. The solvent is dichloromethane (CH2Cl2). The molar ratio of the compound of formula (A) to the compound of formula (B) is 1:1-3 (preferably 1:1). The volume of the solvent used is 5-15 mL / mmol (preferably 10 mL / mmol) based on the amount of the compound of formula (A).

[0018] The present invention also provides a method for preparing a thiourea compound represented by formula (II), the method comprising the following steps:

[0019]

[0020] In the presence of a solvent, the compound of formula (C) and the compound of formula (D) are heated to 80°C, and after the reaction is complete under argon (Ar) protection and magnetic stirring (preferably 4 hours), the reaction solution does not need to be separated and purified by column chromatography, and only the solvent needs to be evaporated to obtain the compound of formula (II); the solvent is anhydrous acetonitrile (CH3CN); the R2 group in the compound of formula (D) is one or more substituted, and the R2 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

[0021] That is, the following reaction occurs:

[0022]

[0023] Furthermore, the preparation method of the thiourea compound represented by formula (II) is carried out according to the following steps: adding the compound of formula (C) to a solvent, stirring and dissolving, slowly dropping the compound of formula (D), controlling the dropping speed to 2-4 mL / min, placing it on a magnetic stirrer under argon (Ar) protection and heating it to 80° C., stirring and reacting for 4 hours, and performing thin layer chromatography monitoring with petroleum ether: ethyl acetate (PE: EA) with a volume ratio of 3:1 as a developing solvent during the reaction. The product presents a single absorption point under ultraviolet light, and the relative shift value (R f The reaction is complete when the reaction mixture is 0.4-0.6, and the reaction solution does not need to be separated and purified by column chromatography. The solvent can be evaporated by a rotary evaporator to obtain the compound of formula (II). The bottle can also be opened in a fume hood and evaporated naturally overnight. The solvent is anhydrous acetonitrile (CH3CN). The molar ratio of the compound of formula (C) to the compound of formula (D) is 1:1-3 (preferably 1:1). The volume of the solvent used is 5-15 mL / mol (preferably 10 mL / mol) based on the amount of the compound of formula (C).

[0024] The present invention also provides a method for preparing a thiourea compound represented by formula (III), the method comprising the following steps:

[0025]

[0026] In the presence of a solvent, after the compound of formula (E) and the compound of formula (F) react completely at room temperature under magnetic stirring, the reaction solution does not need to be separated and purified by column chromatography, and the solvent can be evaporated to obtain the compound of formula (III); the solvent is dichloromethane (CH2Cl2); the R3 group in the compound of formula (F) is one or more substituted, and the R3 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

[0027] That is, the following reaction occurs:

[0028]

[0029] Furthermore, the preparation method of the thiourea compound represented by formula (III) is carried out according to the following steps: adding the compound of formula (E) to a solvent, stirring and dissolving, slowly dropping the compound of formula (F), controlling the dropping speed to 2-4 mL / min, placing on a magnetic stirrer at room temperature to react completely (preferably 2 hours), and performing thin layer chromatography monitoring with ethyl acetate (EA) as a developing agent during the reaction. The product exhibits a single absorption point under ultraviolet light, and the specific shift value (R f The reaction is complete when the reaction mixture is molten by a rotary evaporator without the need for column chromatography separation and purification, and the compound of formula (III) is obtained. The bottle can also be opened in a fume hood and evaporated overnight. The solvent is dichloromethane (CH2Cl2). The molar ratio of the compound of formula (E) to the compound of formula (F) is 1:1-3 (preferably 1:1). The volume of the solvent used is 5-15 mL / mmol (preferably 10 mL / mmol) based on the amount of the compound of formula (E).

[0030] In the present invention, the reaction temperature can be carried out in a wide range, preferably room temperature. If the reaction limit is small under room temperature conditions, it is necessary to further select different solvents according to actual conditions to increase the temperature of the reaction system (close to the boiling point of the corresponding solvent to achieve reflux state); all of the above-mentioned target compounds do not need to be separated and purified by column chromatography.

[0031] The present invention also provides an application of the urea or thiourea compound in the preparation of a β-glucuronidase activity inhibitor. The activity inhibitor is a compound represented by formula (I), (II), (III), or a pharmaceutically acceptable salt thereof.

[0032] Furthermore, the β-glucuronidase is Escherichia coli β-glucuronidase.

[0033] The present invention also provides an application of the urea or thiourea compound in preparing a drug for treating adverse gastrointestinal reactions, wherein the drug includes a drug for treating diarrhea, vomiting or loss of appetite.

[0034] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in:

[0035] The urea or thiourea compounds provided by the present invention have a simple preparation method and a high yield; the compounds exhibit obvious inhibitory activity on βGUS, have good biological activity, and can be used as βGUS inhibitors; and expand the application prospects of benzoazole heterocyclic rings and substituted benzene structures in βGUS inhibitors. (IV) Description of the drawings

[0036] Figure 1 The H NMR spectrum of the compound represented by formula (I-1) 1 H NMR) spectrum.

[0037] Figure 2 The carbon NMR spectrum of the compound represented by formula (I-1) 13 C NMR) graph.

[0038] Figure 3 The H NMR spectrum of the compound represented by formula (II-1) 1 H NMR) spectrum.

[0039] Figure 4 The carbon NMR spectrum of the compound represented by formula (II-1) 13 C NMR) graph.

[0040] Figure 5 The H NMR spectrum of the compound represented by formula (III-1) 1 H NMR) spectrum.

[0041] Figure 6 The carbon NMR spectrum of the compound represented by formula (III-1) 13 C NMR) graph. (V) Specific implementation methods

[0042] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto:

[0043] The room temperature in the present invention refers to 25°C, and the temperature set during constant temperature heating is determined according to the boiling point of the selected solvent (slightly lower than the boiling point of the solvent for reflux). Unless otherwise specified, the reagents and methods involved in the examples are commonly used in the art.

[0044] Example 1. Preparation of Compound (I-1)

[0045]

[0046] In a 25 mL eggplant-shaped flask, add 0.067 g of 2-aminobenzoxazole A (0.5 mmol, 1.0 eqv) dry powder and 5 mL of dichloromethane (CH2Cl2) and stir, slowly add 0.061 mL of 2-fluoroisocyanate phenyl B-1 (0.5 mmol, 1.0 eqv), and control the drop rate to 2-4 mL / min. Place the reaction container on a magnetic stirrer for automatic stirring for 2 hours at room temperature. During the reaction, petroleum ether: ethyl acetate (PE: EA) with a volume ratio of 3: 1 was used as the developing solvent, and thin layer chromatography (TLC) was performed on a GF-254 silica gel plate under ultraviolet light with a wavelength of 254 nm. The product showed a single absorption point under ultraviolet light, and the relative shift value (R f The reaction is complete when the reaction mixture is 0.43. The reaction mixture does not need to be separated and purified by column chromatography. The solvent is evaporated by a rotary evaporator to obtain the compound of formula (I-1). The bottle can also be opened in a fume hood and evaporated overnight to obtain 0.130 g of a yellow solid, namely 1-(2-benzoxazolyl)-3-(2-fluorophenyl)urea (I-1). The total yield of the one-step reaction is 96%. 1 H NMR spectra Figure 1 , 13 C NMR spectra Figure 2 .

[0047] Example 2-11, Preparation of Compounds (I-2) to (I-11)

[0048] Using the method of Example 1, the substituents of compound B-1 were replaced according to Table 1, and other operations were the same to obtain compounds of formula (I-2) to (I-11). The appearance, yield and high resolution mass spectrometry (HRMS) data of the above compounds are listed in Table 1, and the nuclear magnetic resonance (NMR) data are listed in Table 2. It can be seen from the above that the structures of the above compounds are correct and they are all compounds of formula (I).

[0049] Example 12. Preparation of Compound (II-1)

[0050]

[0051] In a 25 mL eggplant flask, add 0.067 g of 2-aminobenzimidazole C (0.5 mmol, 1.0 eqv) dry powder and 5 mL of anhydrous acetonitrile (CH3CN) and stir, slowly add 0.067 mL of 2-fluoroisothiocyanate D-1 (0.5 mmol, 1.0 eqv), and control the drop rate to 2-4 mL / min. Under the protection of argon (Ar), place the reaction vessel on a magnetic stirrer and heat to 80 ° C. and stir automatically for 4 hours. During the reaction, petroleum ether: ethyl acetate (PE: EA) with a volume ratio of 3: 1 was used as the developing solvent. Thin layer chromatography (TLC) was performed on a GF-254 silica gel plate under ultraviolet light with a wavelength of 254 nm. The product showed a single absorption point under ultraviolet light, and the ratio shift value (R f The reaction is complete when the reaction mixture is 0.56. The reaction mixture does not need to be separated and purified by column chromatography. The solvent is evaporated by a rotary evaporator to obtain the compound of formula (II-1). Alternatively, the bottle mouth can be opened in a fume hood and naturally evaporated overnight to obtain 0.133 g of a beige solid, namely 1-(2-benzimidazolyl)-3-(2-fluorophenyl)thiourea (II-1). The total yield of the one-step reaction is 93%. 1 H NMR spectra Figure 3 , 13 C NMR spectra Figure 4 .

[0052] Example 13-24, Preparation of Compounds (II-2) to (II-11)

[0053] Using the method of Example 12, the substituents of compound D-1 were replaced according to Table 1, and other operations were the same to obtain compounds of formula (II-2) to (II-11). The appearance, yield and high resolution mass spectrometry (HRMS) data of the above compounds are listed in Table 1, and the nuclear magnetic resonance (NMR) data are listed in Table 2. It can be seen from the above that the structures of the above compounds are correct and they are all compounds of formula (II).

[0054] Example 25. Preparation of Compound (III-1)

[0055]

[0056] In a 25mL eggplant-shaped flask, add 0.067g of 6-aminobenzimidazole E (0.5mmol, 1.0eqv) dry powder and 5mL of dichloromethane (CH2Cl2) and stir, slowly add 0.067mL of 2-fluoroisothiocyanate phenyl F-1 (0.5mmol, 1.0eqv), and control the drop rate to 2-4mL / min, and place the reaction container on a magnetic stirrer for automatic stirring for 2h at room temperature. During the reaction, ethyl acetate (EA) was used as the developing solvent, and thin layer chromatography (TLC) was performed on a GF-254 silica gel plate under ultraviolet light with a wavelength of 254nm. The product showed a single absorption point under ultraviolet light, R f The reaction is complete when the ratio of transfer is 0.59. The reaction solution does not need to be separated and purified by column chromatography. The solvent is evaporated by a rotary evaporator to obtain the compound of formula (III-1); the bottle mouth can also be opened in a fume hood and evaporated overnight to obtain 0.140 g of a white solid, namely 1-(6-benzimidazolyl)-3-(2-fluorophenyl)thiourea (III-1), and the total yield of the one-step reaction is 98%. 1 H NMR spectra Figure 5 , 13 C NMR spectra Figure 6 .

[0057] Examples 26-37, Preparation of Compounds (III-2) to (III-11)

[0058] Using the method of Example 25, the substituents of compound F-1 were replaced according to Table 1, and other operations were the same to obtain compounds of formula (III-2) to (III-11). The appearance, yield and high resolution mass spectrometry (HRMS) data of the above compounds are listed in Table 1, and the nuclear magnetic resonance (NMR) data are listed in Table 2. It can be seen from the above that the structures of the above compounds are correct and they are all compounds of formula (III).

[0059] Table 1 Appearance, yield and HRMS data of compounds

[0060]

[0061] Table 2 NMR data of compounds

[0062]

[0063]

[0064]

[0065]

[0066]

[0067] Example 38. Screening of the inhibitory activity of urea or thiourea compounds represented by formula (I), (II) and (III) on βGUS

[0068] Enzyme solution: Escherichia coli β-glucuronidase (EcGUS) was dissolved in PBS buffer to prepare a 2 mg / mL solution and added to the well plate at a final concentration of 10 -4 mg / mL.

[0069] Substrate: p-Nitrophenyl-β-D-pyranoglucopyranoside (PNPG) was dissolved in PBS buffer to prepare a 10 mM solution, and then diluted to 2.5 mM with PBS buffer. The final concentration added to the well plate was 250 μM.

[0070] Experimental group inhibitor: The test compound prepared in Example 1-37 was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mM solution, and then diluted to 1 mM with PBS buffer. The final concentration added to the well plate was 100 μM.

[0071] Positive control drug: D-glucaroyl-1,4-lactone (DSL) was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mM solution, and then diluted to 1 mM with PBS buffer. The final concentration added to the well plate was 100 μM.

[0072] Test method: The in vitro enzyme inhibition activity test of the compound was carried out by colorimetric analysis. The specific operation is as follows:

[0073] Prepare 1 mM p-nitrophenol (PNP) solution and add 0, 10, 20, 40, 60, and 80 μL to a 96-well plate, fill to 100 μL with PBS buffer, incubate at 37°C for 30 min, and measure the absorbance at 405 nm (OD 405nm ), with PNP concentration as the horizontal axis and absorbance as the vertical axis, the PNP standard curve was prepared using Excel software, and the curve equation was y=3.262x.

[0074] 10 μL enzyme solution, 70 μL PBS buffer, 10 μL PBS (negative control group) / DSL (positive control group) / inhibitor (experimental group), and 10 μL substrate were added to the 96-well plate in sequence. After adding the substrate, the absorbance at 405 nm was immediately read on the microplate reader, which was recorded as 0 min (OD 0min ), and the PNP concentration at 0 min was obtained according to the PNP standard curve (c 0min ); incubate at 37°C for 30 min, then measure the absorbance, recorded as 30 min (OD 30min ), and the PNP concentration at 30 min was obtained according to the PNP standard curve (c 30min ).

[0075] According to formula (1), the absorbance difference (x) is obtained by subtracting the absorbance at two time points. According to formula (2), the PNP concentration difference (y) is calculated, according to formula (3), the relative activity (RA) of the test compound is calculated, and according to formula (4), its inhibition rate (IR) is calculated. EG refers to the experimental group (containing the target compound or positive control drug), and CG refers to the blank control group (without inhibitor).

[0076] The calculation formula is as follows:

[0077] Absorbance difference x = ΔOD 405nm =OD 30min -OD 0min Formula (1)

[0078] PNP concentration difference y = Δc PNP =c 30min -c 0min Formula (2)

[0079]

[0080] Inhibition rate IR = 1-RA Formula (4)

[0081] The βGUS inhibitory activity of the test compounds was determined by colorimetric analysis, and the results are shown in Table 3. As shown in Table 3, the target compounds exhibited different βGUS inhibitory activities, among which compounds (III-6), (III-9) and (III-13) had good βGUS inhibitory activity, especially compound (III-9), which was better than the positive control DSL and had great development potential.

[0082] Table 3 Inhibition rate of compounds on βGUS (final concentration 100 μM)

[0083] serial number Inhibition rate (%) serial number Inhibition rate (%) serial number Inhibition rate (%) Ⅰ-1 46.9±5.5 Ⅱ-1 30.3±0.8 Ⅲ-1 35.6±1.6 Ⅰ-2 47.3±5.2 Ⅱ-2 26.6±3.7 Ⅲ-2 44.4±4.3 Ⅰ-3 44.3±3.9 Ⅱ-3 21.5±2.0 Ⅲ-3 40.1±2.2 Ⅰ-4 40.3±4.3 Ⅱ-4 19.0±7.3 Ⅲ-4 44.2±6.9 Ⅰ-5 31.1±4.3 Ⅱ-5 33.7±1.9 Ⅲ-5 44.7±2.1 Ⅰ-6 36.9±3.3 Ⅱ-6 31.5±3.1 Ⅲ-6 57.8±2.3 Ⅰ-7 32.1±3.0 Ⅱ-7 21.7±8.0 Ⅲ-7 40.0±5.6 Ⅰ-8 28.2±1.6 Ⅱ-8 18.0±7.1 Ⅲ-8 33.7±7.6 Ⅰ-9 25.4±1.6 Ⅱ-9 13.2±7.5 Ⅲ-9 94.3±1.5 Ⅰ-10 30.2±3.5 Ⅱ-10 18.2±5.7 Ⅲ-10 30.8±6.0 Ⅰ-11 17.7±9.5 Ⅱ-11 19.3±1.7 Ⅲ-11 37.0±2.8 DSL 76.2±3.0 Ⅱ-12 20.9±0.3 Ⅲ-12 30.9±1.4 - - Ⅱ-13 37.5±3.4 Ⅲ-13 63.8±1.6

[0084] Example 39: IC of Compound (III-9) for βGUS 50 Value Research

[0085] Enzyme solution: Escherichia coli β-glucuronidase (EcGUS) was dissolved in PBS buffer to prepare a 2 mg / mL solution and added to the well plate at a final concentration of 10 -4 mg / mL.

[0086] Substrate: p-Nitrophenyl-β-D-pyranoglucopyranoside (PNPG) was dissolved in PBS buffer to prepare a 10 mM solution, and then diluted to 2.5 mM with PBS buffer. The final concentration added to the well plate was 250 μM.

[0087] Inhibitors in the experimental group: The test compound (III-9) was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mM solution, and then diluted to different concentrations with PBS buffer. The final concentrations added to the well plate were 50 μM, 30 μM, 10 μM, 5 μM, 3 μM, 1 μM, 0.5 μM, 0.3 μM, and 0.1 μM.

[0088] Positive control drug: D-glucaroyl-1,4-lactone (DSL) was dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 mM solution, and then diluted to different concentrations with PBS buffer. The final concentrations added to the well plate were 500 μM, 300 μM, 100 μM, 50 μM, 30 μM, 10 μM, 5 μM, 3 μM, and 1 μM.

[0089] Test method: The in vitro enzyme inhibition activity test of the compound was carried out by colorimetric analysis. The specific operation is as follows:

[0090] 10 μL enzyme solution, 70 μL PBS buffer, 10 μL PBS (negative control group) / DSL (positive control group) / inhibitor (experimental group), and 10 μL substrate were added to the 96-well plate in sequence. After adding the substrate, the absorbance at 405 nm was immediately read on the microplate reader, which was recorded as 0 min (OD 0min ), and the PNP concentration (c 0min ); incubate at 37°C for 30 min, then measure the absorbance, recorded as 30 min (OD 30min ), and the PNP concentration (c 30min ).

[0091] According to formula (1), the absorbance difference at two time points is calculated to obtain the absorbance difference (x). According to formula (2), the PNP concentration difference (y) is calculated, according to formula (3), the relative activity (RA) of the test compound is calculated, and according to formula (4), its inhibition rate (IR) is calculated. EG refers to the experimental group (containing the target compound or the positive control drug), and CG refers to the blank control group (containing no inhibitor). The calculation formula is the same as that in Example 38.

[0092] IC was plotted in GraphPad Prism software using PNP concentration differences and relative activity at different inhibitor concentrations. 50 Value curve, get IC 50 The results are shown in Table 4. As shown in Table 4, compound (III-9) has good βGUS inhibitory activity, which is 17 times that of the positive control inhibitor DSL, and has great development potential.

[0093] Table 4 IC of compound (III-9) for βGUS50 value

[0094] serial number <![CDATA[IC 50 (μM)]]> Ⅲ-9 2.7 DSL 45.8

[0095] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention should not be limited by the above embodiments. The contents described in the above embodiments and the specification are only for illustrating the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may also have various optimizations and improvements, and these optimizations and improvements all fall within the scope of protection of the present invention.

Claims

1. A urea or thiourea compound, characterized in that: The structure of the urea compound is shown in formula (I), and the structure of the thiourea compound is shown in formula (II) and (III): The R1 group in formula (Ⅰ) is one or more substituted, and the R1 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano; the R2 group in formula (Ⅱ) and the R3 group in formula (Ⅲ) are the same as the R1 group in formula (Ⅰ).

2. A method for preparing the urea compound represented by formula (I) according to claim 1, characterized in that: The method comprises the following steps: In the presence of a solvent, the compound of formula (A) and the compound of formula (B) react completely at room temperature under magnetic stirring, and then the solvent is evaporated from the reaction solution to obtain the compound of formula (I); the solvent is dichloromethane; the R1 group in the compound of formula (B) is one or more substituted, and the R1 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

3. The preparation method according to claim 2, characterized in that: The preparation method of the urea compound represented by formula (I) is carried out according to the following steps: adding the compound of formula (A) into a solvent, stirring and dissolving, slowly dropping the compound of formula (B), controlling the dropping speed to 2-4 mL / min, placing on a magnetic stirrer at room temperature to react for 2 h, and performing thin layer chromatography monitoring with petroleum ether:ethyl acetate in a volume ratio of 3:1 as a developing solvent during the reaction. The product exhibits a single absorption point under ultraviolet light, R f The reaction is complete when the value is between 0.3 and 0.

5. The reaction solution is evaporated by a rotary evaporator to dry the solvent to obtain the compound of formula (I). The bottle mouth can also be opened in a fume hood and evaporated naturally overnight. The molar ratio of the compound of formula (A) to the compound of formula (B) is 1:1-3. The volume of the solvent used is 5-15 mL / mmol based on the amount of the compound of formula (A).

4. A method for preparing the thiourea compound represented by formula (II) according to claim 1, characterized in that: The method comprises the following steps: In the presence of a solvent, the compound of formula (C) and the compound of formula (D) are heated to 80°C. After the reaction is complete under argon protection and magnetic stirring, the reaction solution is evaporated to dry the solvent to obtain a compound of formula (II); the solvent is anhydrous acetonitrile; the R2 group in the compound of formula (D) is one or more substituted, and the R2 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

5. The method according to claim 4, characterized in that The preparation method of the thiourea compound represented by formula (II) is carried out according to the following steps: adding the compound of formula (C) into a solvent, stirring and dissolving, slowly dropping the compound of formula (D), controlling the dropping speed to 2-4 mL / min, placing on a magnetic stirrer under argon protection and heating to 80° C., stirring and reacting for 4 hours, and performing thin layer chromatography monitoring with petroleum ether:ethyl acetate in a volume ratio of 3:1 as a developing solvent during the reaction. The product presents a single absorption point under ultraviolet light, R f The value is between 0.4 and 0.6, and the reaction is complete. The reaction solution is evaporated by a rotary evaporator to dry the solvent to obtain the compound of formula (II). The bottle mouth can also be opened in a fume hood and naturally evaporated overnight. The molar ratio of the compound of formula (C) to the compound of formula (D) is 1:1-3, and the volume of the solvent used is 5-15mL / mol based on the amount of the compound of formula (C).

6. A method for preparing the thiourea compound represented by formula (III) according to claim 1, characterized in that: The method comprises the following steps: In the presence of a solvent, the compound of formula (E) and the compound of formula (F) react completely at room temperature under magnetic stirring, and then the solvent is evaporated from the reaction solution to obtain a compound of formula (III); the solvent is dichloromethane; the R3 group in the compound of formula (F) is one or more substituted, and the R3 group is one of methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, difluoromethyl, methyl, ethyl, propyl, butyl, tert-butyl, nitro or cyano.

7. The preparation method according to claim 6, characterized in that: The preparation method of the thiourea compound represented by formula (III) is carried out according to the following steps: adding the compound of formula (E) into a solvent, stirring and dissolving, slowly dropping the compound of formula (F), controlling the dropping speed to 2-4 mL / min, placing on a magnetic stirrer at room temperature to react for 2 h, and performing thin layer chromatography monitoring with ethyl acetate as a developing agent during the reaction. The product exhibits a single absorption point under ultraviolet light, R f The value is between 0.5 and 0.7, and the reaction is complete. The reaction solution is evaporated by a rotary evaporator to dry the solvent to obtain the compound of formula (III). The bottle mouth can also be opened in a fume hood and naturally evaporated overnight. The molar ratio of the compound of formula (E) to the compound of formula (F) is 1:1-3, and the volume of the solvent used is 5-15mL / mmol based on the amount of the compound of formula (E).

8. Use of the urea or thiourea compound according to claim 1 in the preparation of a β-glucuronidase inhibitor.

9. The use according to claim 8, characterized in that The β-glucuronidase is Escherichia coli β-glucuronidase.

10. Use of the urea or thiourea compound in preparing a drug for treating adverse gastrointestinal reactions.

Citation Information

Patent Citations

  • Benzo five-membered and six-membered ring (thio) urea catalyst and application thereof in ring-opening polymerization

    CN111704714A

  • Novel inhibitors of glutaminyl cyclase

    US20080262063A1

  • Novel inhibitors of glutaminyl cyclase

    US20080286231A1